A combined ligand-based and target-based drug design approach for G-protein coupled receptors: Application to salvinorin A, a selective kappa opioid receptor agonist

Nidhi Singh, Gwénaël Chevé, David M. Ferguson, Christopher R. McCurdy

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Combined ligand-based and target-based drug design approaches provide a synergistic advantage over either method individually. Therefore, we set out to develop a powerful virtual screening model to identify novel molecular scaffolds as potential leads for the human KOP (hKOP) receptor employing a combined approach. Utilizing a set of recently reported derivatives of salvinorin A, a structurally unique KOP receptor agonist, a pharmacophore model was developed that consisted of two hydrogen bond acceptor and three hydrophobic features. The model was cross-validated by randomizing the data using the CatScramble technique. Further validation was carried out using a test set that performed well in classifying active and inactive molecules correctly. Simultaneously, a bovine rhodopsin based "agonist-bound" hKOP receptor model was also generated. The model provided more accurate information about the putative binding site of salvinorin A based ligands. Several protein structure-checking programs were used to validate the model. In addition, this model was in agreement with the mutation experiments carried out on KOP receptor. The predictive ability of the model was evaluated by docking a set of known KOP receptor agonists into the active site of this model. The docked scores correlated reasonably well with experimental pKi values. It is hypothesized that the integration of these two independently generated models would enable a swift and reliable identification of new lead compounds that could reduce time and cost of hit finding within the drug discovery and development process, particularly in the case of GPCRs.

Original languageEnglish (US)
Pages (from-to)471-493
Number of pages23
JournalJournal of Computer-Aided Molecular Design
Volume20
Issue number7-8
DOIs
StatePublished - Aug 1 2006

Fingerprint

salvinorin A
kappa Opioid Receptor
Drug Design
G-Protein-Coupled Receptors
drugs
Ligands
proteins
Proteins
ligands
Rhodopsin
Drug Discovery
Pharmaceutical Preparations
Hydrogen
Catalytic Domain
Binding Sites
Costs and Cost Analysis
Mutation
Lead compounds
lead compounds

Keywords

  • Comparative modeling
  • Docking
  • G-protein coupled receptor (GPCR)
  • Homology
  • Kappa opioid receptor
  • Modeler
  • Molecular dynamics
  • New molecular entities (NMEs)
  • Pharmacophore
  • Salvinorin A

Cite this

A combined ligand-based and target-based drug design approach for G-protein coupled receptors : Application to salvinorin A, a selective kappa opioid receptor agonist. / Singh, Nidhi; Chevé, Gwénaël; Ferguson, David M.; McCurdy, Christopher R.

In: Journal of Computer-Aided Molecular Design, Vol. 20, No. 7-8, 01.08.2006, p. 471-493.

Research output: Contribution to journalArticle

@article{135f58bf6e1a419bb02d4222de3c4f6d,
title = "A combined ligand-based and target-based drug design approach for G-protein coupled receptors: Application to salvinorin A, a selective kappa opioid receptor agonist",
abstract = "Combined ligand-based and target-based drug design approaches provide a synergistic advantage over either method individually. Therefore, we set out to develop a powerful virtual screening model to identify novel molecular scaffolds as potential leads for the human KOP (hKOP) receptor employing a combined approach. Utilizing a set of recently reported derivatives of salvinorin A, a structurally unique KOP receptor agonist, a pharmacophore model was developed that consisted of two hydrogen bond acceptor and three hydrophobic features. The model was cross-validated by randomizing the data using the CatScramble technique. Further validation was carried out using a test set that performed well in classifying active and inactive molecules correctly. Simultaneously, a bovine rhodopsin based {"}agonist-bound{"} hKOP receptor model was also generated. The model provided more accurate information about the putative binding site of salvinorin A based ligands. Several protein structure-checking programs were used to validate the model. In addition, this model was in agreement with the mutation experiments carried out on KOP receptor. The predictive ability of the model was evaluated by docking a set of known KOP receptor agonists into the active site of this model. The docked scores correlated reasonably well with experimental pKi values. It is hypothesized that the integration of these two independently generated models would enable a swift and reliable identification of new lead compounds that could reduce time and cost of hit finding within the drug discovery and development process, particularly in the case of GPCRs.",
keywords = "Comparative modeling, Docking, G-protein coupled receptor (GPCR), Homology, Kappa opioid receptor, Modeler, Molecular dynamics, New molecular entities (NMEs), Pharmacophore, Salvinorin A",
author = "Nidhi Singh and Gw{\'e}na{\"e}l Chev{\'e} and Ferguson, {David M.} and McCurdy, {Christopher R.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1007/s10822-006-9067-x",
language = "English (US)",
volume = "20",
pages = "471--493",
journal = "Journal of Computer-Aided Molecular Design",
issn = "0920-654X",
publisher = "Springer Netherlands",
number = "7-8",

}

TY - JOUR

T1 - A combined ligand-based and target-based drug design approach for G-protein coupled receptors

T2 - Application to salvinorin A, a selective kappa opioid receptor agonist

AU - Singh, Nidhi

AU - Chevé, Gwénaël

AU - Ferguson, David M.

AU - McCurdy, Christopher R.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Combined ligand-based and target-based drug design approaches provide a synergistic advantage over either method individually. Therefore, we set out to develop a powerful virtual screening model to identify novel molecular scaffolds as potential leads for the human KOP (hKOP) receptor employing a combined approach. Utilizing a set of recently reported derivatives of salvinorin A, a structurally unique KOP receptor agonist, a pharmacophore model was developed that consisted of two hydrogen bond acceptor and three hydrophobic features. The model was cross-validated by randomizing the data using the CatScramble technique. Further validation was carried out using a test set that performed well in classifying active and inactive molecules correctly. Simultaneously, a bovine rhodopsin based "agonist-bound" hKOP receptor model was also generated. The model provided more accurate information about the putative binding site of salvinorin A based ligands. Several protein structure-checking programs were used to validate the model. In addition, this model was in agreement with the mutation experiments carried out on KOP receptor. The predictive ability of the model was evaluated by docking a set of known KOP receptor agonists into the active site of this model. The docked scores correlated reasonably well with experimental pKi values. It is hypothesized that the integration of these two independently generated models would enable a swift and reliable identification of new lead compounds that could reduce time and cost of hit finding within the drug discovery and development process, particularly in the case of GPCRs.

AB - Combined ligand-based and target-based drug design approaches provide a synergistic advantage over either method individually. Therefore, we set out to develop a powerful virtual screening model to identify novel molecular scaffolds as potential leads for the human KOP (hKOP) receptor employing a combined approach. Utilizing a set of recently reported derivatives of salvinorin A, a structurally unique KOP receptor agonist, a pharmacophore model was developed that consisted of two hydrogen bond acceptor and three hydrophobic features. The model was cross-validated by randomizing the data using the CatScramble technique. Further validation was carried out using a test set that performed well in classifying active and inactive molecules correctly. Simultaneously, a bovine rhodopsin based "agonist-bound" hKOP receptor model was also generated. The model provided more accurate information about the putative binding site of salvinorin A based ligands. Several protein structure-checking programs were used to validate the model. In addition, this model was in agreement with the mutation experiments carried out on KOP receptor. The predictive ability of the model was evaluated by docking a set of known KOP receptor agonists into the active site of this model. The docked scores correlated reasonably well with experimental pKi values. It is hypothesized that the integration of these two independently generated models would enable a swift and reliable identification of new lead compounds that could reduce time and cost of hit finding within the drug discovery and development process, particularly in the case of GPCRs.

KW - Comparative modeling

KW - Docking

KW - G-protein coupled receptor (GPCR)

KW - Homology

KW - Kappa opioid receptor

KW - Modeler

KW - Molecular dynamics

KW - New molecular entities (NMEs)

KW - Pharmacophore

KW - Salvinorin A

UR - http://www.scopus.com/inward/record.url?scp=34249277652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249277652&partnerID=8YFLogxK

U2 - 10.1007/s10822-006-9067-x

DO - 10.1007/s10822-006-9067-x

M3 - Article

C2 - 17009091

AN - SCOPUS:34249277652

VL - 20

SP - 471

EP - 493

JO - Journal of Computer-Aided Molecular Design

JF - Journal of Computer-Aided Molecular Design

SN - 0920-654X

IS - 7-8

ER -